Hsbc Holdings PLC Buys 9,888 Shares of Bruker Co. (NASDAQ:BRKR)

Hsbc Holdings PLC raised its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,574 shares of the medical research company's stock after purchasing an additional 9,888 shares during the period. Hsbc Holdings PLC's holdings in Bruker were worth $1,499,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of BRKR. Eagle Bay Advisors LLC raised its stake in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. lifted its stake in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after purchasing an additional 248 shares during the period. Quadrant Capital Group LLC boosted its holdings in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after purchasing an additional 412 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Bruker by 41.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after buying an additional 390 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Up 2.8 %

Shares of NASDAQ:BRKR opened at $40.44 on Friday. Bruker Co. has a 52 week low of $34.10 and a 52 week high of $79.78. The company has a market capitalization of $6.13 billion, a PE ratio of 53.21, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a 50 day moving average price of $42.05 and a two-hundred day moving average price of $51.95.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Analysts forecast that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's dividend payout ratio (DPR) is currently 26.32%.

Analyst Ratings Changes

Several brokerages have recently commented on BRKR. Barclays reduced their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a report on Monday, February 24th. Wells Fargo & Company lowered their target price on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Finally, Stifel Nicolaus lowered their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $65.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.